EASL 2022

EASL 2022
June 22-26, 2022
Virtual Conference

The International Liver Congress 2022: European Association for the Study of the Liver.

Explore more information for Gilead Liver Diseases therapies
Results (11)

Polymorphic analysis of bulevirtide sequence in PreS1 of large HBsAg across HBV genotypes A-H

Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta

No detectable resistance to bulevirtide in participants with chronic hepatitis D (CHD) through 24 weeks of treatment

Evaluation of renal and bone safety at 4 years in post-liver transplant patients with chronic kidney disease receiving Tenofovir Alafenamide for HBV prophylaxis

Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary endpoint results from a phase 3 randomized, multicenter, parallel design study

Impact of patient-related factors on the pharmacokinetics of Bulevirtide

Randomized, double-blind, placebo-controlled trial of Tenofovir Alafenamide in children and adolescents with chronic hepatitis B

Bulevirtide is broadly active against all HDV genotypes expressing envelopes from HBV genotypes A-H and a large panel of clinical isolates

Decrease in the burden of integrated hepatitis B virus DNA in chronic hepatitis B patients with minimally elevated alanine aminotransferase on tenofovir disoproxil fumarate as revealed by long-read DNA-sequencing

Safety and efficacy of the farnesoid X receptor (FXR) agonist cilofexor in a proof-of-concept study in patients with compensated cirrhosis due to primary sclerosing cholangitis (PSC)

Integrated safety analysis of 24-week data from three phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg and 10 mg dose level for treatment of chronic hepatitis delta